Compare Stocks: INVA, WEN, NBR, and GSK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GSK GSK	$51.72 -0.7%	$51.73	$36.75 ▼ $61.69	$105.32B	0.35	4.40 million shs	3.98 million shs
INVA Innoviva	$20.97 -1.2%	$22.19	$16.52 ▼ $25.15	$1.57B	0.34	733,720 shs	507,992 shs
NBR Nabors Industries	$85.28 +3.7%	$87.61	$30.90 ▼ $112.90	$1.22B	0.96	246,510 shs	356,164 shs
WEN Wendy's	$7.36	$7.40	$6.07 ▼ $10.84	$1.40B	0.36	8.59 million shs	5.31 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GSK GSK	-2.13%	+2.43%	-0.80%	-0.73%	+33.37%
INVA Innoviva	-1.94%	+0.09%	-6.56%	-7.70%	+15.14%
NBR Nabors Industries	+2.82%	-2.80%	-2.90%	-20.07%	+139.15%
WEN Wendy's	-3.79%	+2.65%	-11.22%	+5.75%	-27.13%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GSK GSK	$51.72 -0.7%	$51.73	$36.75 ▼ $61.69	$105.32B	0.35	4.40 million shs	3.98 million shs
INVA Innoviva	$20.97 -1.2%	$22.19	$16.52 ▼ $25.15	$1.57B	0.34	733,720 shs	507,992 shs
NBR Nabors Industries	$85.28 +3.7%	$87.61	$30.90 ▼ $112.90	$1.22B	0.96	246,510 shs	356,164 shs
WEN Wendy's	$7.36	$7.40	$6.07 ▼ $10.84	$1.40B	0.36	8.59 million shs	5.31 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GSK GSK	-2.13%	+2.43%	-0.80%	-0.73%	+33.37%
INVA Innoviva	-1.94%	+0.09%	-6.56%	-7.70%	+15.14%
NBR Nabors Industries	+2.82%	-2.80%	-2.90%	-20.07%	+139.15%
WEN Wendy's	-3.79%	+2.65%	-11.22%	+5.75%	-27.13%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GSK GSK	2.10	Hold	$53.00	2.47% Upside
INVA Innoviva	2.57	Moderate Buy	$36.20	72.63% Upside
NBR Nabors Industries	2.50	Moderate Buy	$102.00	19.61% Upside
WEN Wendy's	1.86	Reduce	$8.04	9.21% Upside

Current Analyst Ratings Breakdown

Latest INVA, WEN, NBR, and GSK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2026	GSK GSK	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
7/30/2026	NBR Nabors Industries	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$120.00 ➝ $130.00
7/29/2026	GSK GSK	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
7/28/2026	WEN Wendy's	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$7.75 ➝ $7.25
7/24/2026	GSK GSK	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral
7/17/2026	WEN Wendy's	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
7/17/2026	GSK GSK	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/15/2026	NBR Nabors Industries	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/9/2026	GSK GSK	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
7/8/2026	NBR Nabors Industries	Susquehanna Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$105.00 ➝ $85.00
7/6/2026	GSK GSK	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Reduce ➝ Hold

(Data available from 7/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GSK GSK	$43.07B	2.43	$5.97 per share	8.67	$11.40 per share	4.54
INVA Innoviva	$411.33M	3.76	$4.97 per share	4.22	$15.71 per share	1.33
NBR Nabors Industries	$3.21B	0.39	$37.08 per share	2.30	$63.94 per share	1.33
WEN Wendy's	$2.18B	0.64	$1.80 per share	4.09	$0.62 per share	11.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GSK GSK	$7.54B	$3.20	16.17	10.04	2.98	14.56%	43.23%	11.60%	N/A
INVA Innoviva	$271.17M	$6.01	3.49	9.75	N/A	119.89%	33.33%	22.67%	8/5/2026 (Estimated)
NBR Nabors Industries	$286.62M	$13.44	6.35	43.73	N/A	7.64%	-7.06%	-1.45%	N/A
WEN Wendy's	$165.07M	$0.78	9.44	11.87	0.53	6.77%	136.46%	3.14%	8/7/2026 (Estimated)

Latest INVA, WEN, NBR, and GSK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2026	Q2 2026	WEN Wendy's	$0.16	N/A	N/A	N/A	$557.36 million	N/A
8/5/2026	Q2 2026	INVA Innoviva	$0.4360	N/A	N/A	N/A	$110.99 million	N/A
7/28/2026	Q2 2026	NBR Nabors Industries	-$1.30	-$2.04	-$0.74	-$2.04	$809.28 million	$814.80 million
6/30/2026	Q2 2026	NBR Nabors Industries	N/A	-$2.04	N/A	-$2.04	N/A	$814.80 million
5/8/2026	Q1 2026	WEN Wendy's	$0.10	$0.12	+$0.02	$0.12	$518.03 million	$432.30 million
5/6/2026	Q1 2026	INVA Innoviva	$0.43	$0.44	+$0.01	$2.22	$101.57 million	$97.99 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GSK GSK	$1.79	3.46%	-7.86%	55.94%	N/A
INVA Innoviva	N/A	N/A	N/A	N/A	N/A
NBR Nabors Industries	N/A	N/A	-100.00%	N/A	N/A
WEN Wendy's	$0.56	7.61%	+18.23%	71.79%	N/A

Latest INVA, WEN, NBR, and GSK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/28/2026	GSK GSK	quarterly	$0.4515	3.36%	8/14/2026	8/14/2026	10/8/2026
5/8/2026	WEN Wendy's	quarterly	$0.14	7.13%	6/1/2026	6/1/2026	6/15/2026
1/1/2100	GSK GSK	quarterly	$0.4206	4.3%	8/15/2025	8/15/2025	10/9/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GSK GSK	0.81	0.82	0.52
INVA Innoviva	0.19	21.13	20.07
NBR Nabors Industries	2.24	1.89	1.82
WEN Wendy's	29.25	1.83	1.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GSK GSK	15.74%
INVA Innoviva	99.12%
NBR Nabors Industries	81.92%
WEN Wendy's	85.96%

Insider Ownership

Company	Insider Ownership
GSK GSK	10.00%
INVA Innoviva	2.01%
NBR Nabors Industries	5.32%
WEN Wendy's	17.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GSK GSK	66,841	2.02 billion	1.82 billion	Optionable
INVA Innoviva	100	73.81 million	72.33 million	Optionable
NBR Nabors Industries	13,900	14.80 million	14.01 million	Optionable
WEN Wendy's	14,900	190.48 million	157.91 million	Optionable

INVA, WEN, NBR, and GSK Headlines

Recent News About These Companies

Why is Wendy's no longer competing with burger brands alone? And how?

July 31 at 5:11 AM | bestmediainfo.comB

Trying KFC, Wendy's & Starbucks fast food taste test! ☕

July 31 at 5:11 AM | msn.com

The Wendy's Company $WEN Shares Bought by Renaissance Technologies LLC

July 31 at 5:00 AM | marketbeat.com

Wendy's (WEN) to Post Quarterly Earnings on Friday

July 31 at 1:56 AM | americanbankingnews.com

Wendy's (WEN) to Post Earnings on Friday

July 31 at 1:55 AM | marketbeat.com

Why Wendy's Fish Sandwich Isn't Available Year-Round

July 30 at 12:48 PM | yahoo.com

Wendy's could close up to 350 locations

July 30 at 12:48 PM | msn.com

Wendy's Best Lemonade Flavor Is The Perfect Summer Sip In Our Eyes

July 30 at 12:48 PM | aol.comA

The Wendy's Company (NASDAQ:WEN) Given Consensus Rating of "Reduce" by Brokerages

July 30 at 4:43 AM | marketbeat.com

The Wendy's Company $WEN Stake Decreased by Arrowstreet Capital Limited Partnership

July 30 at 3:12 AM | marketbeat.com

Wendy’s sold out of free tote bags in 90 seconds — here’s the lesson for your business

July 28 at 2:55 PM | msn.com

Wendy’s drops price of beloved original menu item to $1

July 28 at 2:55 PM | al.comA

Wendy’s drops price of iconic fast-food treat to $1

July 28 at 2:55 PM | mlive.comM

Citigroup Has Lowered Expectations for Wendy's (NASDAQ:WEN) Stock Price

July 28 at 12:17 PM | marketbeat.com

Wendy’s pretzel baconator & crispy chicken sandwich taste test!

July 28 at 9:55 AM | msn.com

Wendy's Baconator review and drive thru test (lots of bacon!)

July 27, 2026 | msn.com

Healthcare of Ontario Pension Plan Trust Fund Buys Shares of 3,750,000 The Wendy's Company $WEN

July 27, 2026 | marketbeat.com

Comparing Wendy's (NASDAQ:WEN) and Dave & Buster's Entertainment (NASDAQ:PLAY)

July 26, 2026 | americanbankingnews.com

Customers Say These Wendy’s Menu Items Don’t Taste Like They Used To

July 25, 2026 | aol.comA

Local Wendy's location closes as company struggles across U.S.

July 25, 2026 | finance.yahoo.com

Wendy's fans say these classic menu items don't taste like they used to

July 25, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

INVA, WEN, NBR, and GSK Company Descriptions

GSK NYSE:GSK

$51.72 -0.35 (-0.66%)

Closing price 03:59 PM Eastern

Extended Trading

$51.75 +0.03 (+0.05%)

As of 07:43 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Innoviva NASDAQ:INVA

$20.97 -0.25 (-1.18%)

Closing price 04:00 PM Eastern

Extended Trading

$20.96 0.00 (-0.02%)

As of 07:34 PM Eastern

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Nabors Industries NYSE:NBR

$85.28 +3.08 (+3.74%)

Closing price 03:59 PM Eastern

Extended Trading

$85.62 +0.34 (+0.40%)

As of 07:34 PM Eastern

Nabors Industries Ltd. provides drilling and drilling-related services for land-based and offshore oil and natural gas wells in the United States and internationally. The company operates through four segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. It provides tubular running services, including casing and tubing running, and torque monitoring; managed pressure drilling services; and drilling-bit steering systems and rig instrumentation software. The company also offers drilling systems comprising ROCKit, a directional steering control system; SmartNAV, a collaborative guidance and advisory platform; SmartSLIDE, a directional steering control system; and RigCLOUD, a digital infrastructure to integrate applications to deliver real-time insight into operations across the rig fleet. In addition, it operates a fleet of land-based drilling rigs and marketed platforms rigs; manufactures and sells top drives, catwalks, wrenches, drawworks, and other drilling related equipment, such as robotic systems and downhole tools; and provides aftermarket sales and services for the installed base of its equipment. Nabors Industries Ltd. was founded in 1952 and is based in Hamilton, Bermuda.

Wendy's NASDAQ:WEN

$7.36 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$7.36 0.00 (0.00%)

As of 07:56 PM Eastern

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INVA, WEN, NBR, and GSK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INVA, WEN, NBR, and GSK Earnings

Compare Dividends

Latest INVA, WEN, NBR, and GSK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INVA, WEN, NBR, and GSK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INVA, WEN, NBR, and GSK Company Descriptions

GSK NYSE:GSK

Innoviva NASDAQ:INVA

Nabors Industries NYSE:NBR

Wendy's NASDAQ:WEN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools